Lung Cancer | Specialty

Afatinib Plus Cetuximab in Resistant NSCLC

July 16th 2014

AZD9291 and Rociletinib in T790M-Mutant NSCLC

July 16th 2014

Next-Generation EGFR Inhibitors in NSCLC

July 16th 2014

Subgroup Analyses for Nab-Paclitaxel in NSCLC

July 16th 2014

Maintenance Nab-Paclitaxel in Squamous NSCLC

July 16th 2014

Nab-Paclitaxel in Non-Small Cell Lung Cancer

July 16th 2014

Introduction: Exploration of Nab-Paclitaxel in NSCLC

July 16th 2014

Novel Therapies, Strategies in Development for NSCLC

July 16th 2014

The treatment landscape for patients with non-small cell lung cancer (NSCLC) is poised to undergo dramatic changes, as novel immunotherapies, second-generation targeted therapies, and new maintenance strategies continue to show promise in clinical trials.

Nivolumab, Alectinib Gain Approvals in Japan

July 7th 2014

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

Dr. Chachoua Describes Clinical Trials Evaluating Immunotherapy in Lung Cancer

July 2nd 2014

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

Dr. Galbraith Discusses the Development of AZD9291

July 1st 2014

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.

Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC

June 28th 2014

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

Alex Molasiotis, RN, PhD, on the Management on Breathlessness

June 27th 2014

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

50th Anniversary Report: Even More Known About Smoking, Cancer Connections

June 24th 2014

A recent report on the health consequences of smoking pored through the most recent data and several new findings about smoking and cancer.

Dr. Sequist Discusses the Efficacy of CO-1686 for NSCLC

June 23rd 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the efficacy of CO-1686 for the treatment of non-small cell lung cancer.

Docetaxel May Cause Intoxication, FDA Warns

June 20th 2014

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Dr. Sequist Discusses Adverse Events Associated With CO-1686

June 16th 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer.

Dr. Kim Discusses Detecting EGFR and KRAS Mutations from Cell-Free Plasma DNA of NSCLC Patients

June 16th 2014

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of patients with non-small cell lung cancer (NSCLC).

Dr. Piperdi Discusses RICTOR Amplification in Lung Cancer

June 12th 2014

Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.

Continuing Afatinib Beyond Progression Improves PFS in Metastatic NSCLC

June 10th 2014

Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.